Verus Capital Partners LLC Invests $203,000 in Danaher Co. (NYSE:DHR)

Verus Capital Partners LLC purchased a new position in Danaher Co. (NYSE:DHR) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 729 shares of the conglomerate’s stock, valued at approximately $203,000.

Several other institutional investors also recently added to or reduced their stakes in the stock. CarsonAllaria Wealth Management Ltd. purchased a new position in shares of Danaher during the second quarter worth approximately $25,000. nVerses Capital LLC purchased a new position in Danaher during the 2nd quarter worth $25,000. MFA Wealth Advisors LLC bought a new stake in Danaher during the 2nd quarter valued at $51,000. Financial Connections Group Inc. purchased a new stake in shares of Danaher in the 2nd quarter worth $51,000. Finally, Western Pacific Wealth Management LP bought a new position in shares of Danaher during the 1st quarter worth $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is owned by corporate insiders.

Danaher Trading Up 0.8 %

NYSE:DHR opened at $241.47 on Thursday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The firm has a fifty day simple moving average of $263.88 and a 200-day simple moving average of $260.77. Danaher Co. has a 12 month low of $200.36 and a 12 month high of $281.70. The company has a market capitalization of $174.41 billion, a P/E ratio of 46.08, a PEG ratio of 4.40 and a beta of 0.85.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the business earned $2.02 EPS. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. On average, equities research analysts anticipate that Danaher Co. will post 7.51 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher’s dividend payout ratio is presently 20.61%.

Analysts Set New Price Targets

Several analysts recently weighed in on DHR shares. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a report on Thursday, October 31st. Evercore ISI upped their price target on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Royal Bank of Canada cut their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Leerink Partners boosted their price objective on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, StockNews.com upgraded Danaher from a “hold” rating to a “buy” rating in a report on Wednesday, November 6th. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus target price of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.